Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
暂无分享,去创建一个
Karen A Robinson | C. Goss | K. Robinson | P. Flume | B. Marshall | P. Mogayzel | Patrick A Flume | Christopher H Goss | Peter J Mogayzel | R. Kuhn | Randall L Rosenblatt | Robert J Kuhn | Bruce C Marshall | R. Rosenblatt
[1] J. Emerson,et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. , 2007, Chest.
[2] T. Marco,et al. Home intravenous antibiotics for cystic fibrosis. , 2000, The Cochrane database of systematic reviews.
[3] F. Odds,et al. Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.
[4] J. Lapointe,et al. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[5] S. Lewis,et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial , 2005, The Lancet.
[6] J. Bosso,et al. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. , 1987, The American journal of medicine.
[7] P. Bye,et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial , 2005, The Lancet.
[8] R. Swartz,et al. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. , 1998, The New England journal of medicine.
[9] J. Turnidge,et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.
[10] J. Ledbetter,et al. Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. , 1985, The Journal of pediatrics.
[11] U. Schaad,et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. , 1997, The Pediatric infectious disease journal.
[12] A. Giunta,et al. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. , 1987, The Pediatric infectious disease journal.
[13] W. Craig. Re-evaluating current antibiotic therapy , 2001 .
[14] J. Littlewood,et al. Home intravenous antibiotic treatment in cystic fibrosis. , 1988, Archives of disease in childhood.
[15] M. Marks,et al. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? , 1980, The Journal of pediatrics.
[16] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[17] A. Prince,et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Gonzalez de Dios,et al. Home intravenous antibiotics for cystic fibrosis. , 2000, The Cochrane database of systematic reviews.
[19] L. Saiman,et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.
[20] M. Hodson,et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. , 2000, The European respiratory journal.
[21] R. Moore,et al. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. , 1984, The Journal of infectious diseases.
[22] W. Craig. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. , 2001, Respiratory medicine.
[23] M. Tully,et al. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[24] M. Sulis,et al. Pneumothorax in pleuropulmonary Kaposi's sarcoma related to acquired immunodeficiency syndrome. , 1989, The American journal of medicine.
[25] S. Butler,et al. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies , 1999, Pediatric pulmonology.
[26] Charles A. Johnson,et al. Pulmonary exacerbations in cystic fibrosis , 2004, Pediatric pulmonology.
[28] T. Remmington,et al. Oral anti-pseudomonal antibiotics for cystic fibrosis. , 2016, The Cochrane database of systematic reviews.
[29] Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms , 1985, Thorax.
[30] A. Quittner,et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. , 1999, Diabetes research and clinical practice.
[31] H. Neu,et al. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. , 1977, The Journal of pediatrics.
[32] D. Goldmann,et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. , 1983, The Journal of infectious diseases.
[33] C. Goss,et al. Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.
[34] D. Turck,et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis , 1998, Archives of disease in childhood.
[35] Martin H. Schmidt,et al. Epidemiology and Pathogenesis , 2022 .
[36] P. Baghurst,et al. Efficacy of once‐daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study * , 2001, Pediatric pulmonology.
[37] J. Bartlett,et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] H. Fuchs,et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.
[39] J. W. Wong,et al. Mucociliary clearance in cystic fibrosis. , 1976, Modern problems in paediatrics.
[40] S. Conway,et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. , 1997, Thorax.
[41] G. Redding,et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .
[42] R. Moore,et al. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.
[43] R. J. Butland,et al. ORAL CIPROFLOXACIN COMPARED WITH CONVENTIONAL INTRAVENOUS TREATMENT FOR PSEUDOMONAS AERUGINOSA INFECTION IN ADULTS WITH CYSTIC FIBROSIS , 1987, The Lancet.
[44] Karen A Robinson,et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.
[45] K. Robinson,et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. , 2009, Respiratory care.
[46] B. Ramsey,et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. , 2003, Chest.
[47] M. Newport,et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. , 1994, The European respiratory journal.
[48] J. Watkins,et al. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? , 1988, Scandinavian Journal of Gastroenterology, Supplement.
[49] M. Walshaw,et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use , 2005, Pediatric pulmonology.
[50] M. Jackson,et al. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. , 1986, Pediatric infectious disease.
[51] M. Hodson,et al. Inhalation of antibiotics in cystic fibrosis. , 1995, The European respiratory journal.
[52] S. Bowler,et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. , 1997, The European respiratory journal.
[53] I. Abdulhamid,et al. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis , 2006, Pediatric pulmonology.
[54] G. Esmond,et al. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. , 2006, Journal of clinical nursing.
[55] Hodson,et al. Adults with cystic fibrosis , 1990, The Lancet.
[56] W. Ambrosius,et al. Lower respiratory illness in infants and young children with cystic fibrosis , 1997, Pediatric pulmonology.
[57] P. Gilligan,et al. Microbiology of airway disease in patients with cystic fibrosis , 1991, Clinical Microbiology Reviews.
[58] A. Knox,et al. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers , 2002, Pediatric pulmonology.
[59] J. Bosso,et al. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. , 1988, The Pediatric infectious disease journal.
[60] N. Høiby,et al. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. , 1986, Scandinavian journal of infectious diseases.
[61] S. Davis,et al. Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[62] R. Hornung,et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. , 2002, Chest.
[63] D. Geddes,et al. SELF-ADMINISTERED HOME INTRAVENOUS ANTIBIOTIC THERAPY IN BRONCHIECTASIS AND ADULT CYSTIC FIBROSIS , 1984, The Lancet.
[64] Bowerman,et al. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis , 2000, European journal of clinical investigation.
[65] D. Nielson,et al. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis , 1997, Pediatric pulmonology.
[66] M. Falagas,et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. , 2008, The Journal of antimicrobial chemotherapy.
[67] J. Blumer,et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis , 1988, Pediatric pulmonology.
[68] R. Moore,et al. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. , 1984, The American journal of medicine.
[69] E. Atenafu,et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. , 2007, The Journal of antimicrobial chemotherapy.
[70] D. Bilton,et al. Evaluation of Once Daily Tobramycin Versus the Traditional Three Time Daily for the Treatment of Acute Pulmonary Exacerbations in Adult Cystic Fibrosis Patients , 2006 .
[71] G. Redding,et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. , 1999, The Journal of pediatrics.
[72] L. Briceland,et al. Single Daily Dosing of Aminoglycosides , 1995, Pharmacotherapy.
[73] J. Bosso,et al. A Pilot Study of the Efficacy of Constant‐Infusion Ceftazidime in the Treatment of Endobronchial Infections in Adults with Cystic Fibrosis , 1999, Pharmacotherapy.
[74] Diana Petitti,et al. Update on the Methods of the U.S. Preventive Services Task Force: Estimating Certainty and Magnitude of Net Benefit , 2007, Annals of Internal Medicine.
[75] J. Bosso. Use of ciprofloxacin in cystic fibrosis patients. , 1989, The American journal of medicine.
[76] L. Saiman. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. , 2007, Paediatric respiratory reviews.
[77] W. Warwick,et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.
[78] M. Yi,et al. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? , 2004, The Journal of pediatrics.
[79] G. Guyatt,et al. A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.
[80] S. Bogle,et al. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis , 2002, European Respiratory Journal.
[81] H. Levison,et al. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. , 1985, Pediatric infectious disease.
[82] J. Bradley,et al. An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis , 1999, Irish journal of medical science.
[83] J. Ioannidis,et al. Single or multiple daily doses of aminoglycosides: a meta- analysis , 1996, BMJ.
[84] E. Mellits,et al. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. , 1981, The Journal of pediatrics.
[85] H. Auerbach,et al. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. , 1987, The Journal of pediatrics.
[86] A. Smyth,et al. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2017, The Cochrane database of systematic reviews.
[87] M S Pepe,et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.
[88] S. Aaron. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. , 2007, Paediatric respiratory reviews.
[89] R. Baker,et al. Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis , 2002, Journal of pediatric gastroenterology and nutrition.
[90] M. Konstan,et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis , 2008, Pediatric pulmonology.
[91] D. Nicolau. Pharmacodynamic optimization of β-lactams in the patient care setting , 2008, Critical care.